Is There a Retatrutide Shortage? What to Do Next

By The RX Index Editorial Team · Last verified October 17, 2026

There is no FDA-listed retatrutide shortage. Retatrutide is Eli Lilly's experimental weekly shot, still in trials, and is not FDA-approved. There is no approved pharmacy supply to restock. But a study shipment can still be delayed. Your next step depends on whether a study team or a seller supplied it.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Here are the two situations to separate. If you're in a Lilly study and your site says your medicine is late, that's a real supply problem, and your study team owns it. And if your prescription is for Zepbound, Wegovy, Mounjaro, or Ozempic, you're asking about a different, approved drug.

So the useful question isn't "when will it restock?" It's "who handles my next step?" The table below answers that.

RX Index Decision Verdict: Don't replace a vanished seller with a new one. Get a plan from the right clinician first, then pick a lawful path.

• Best for: People whose retatrutide source stopped, got seized, or is running low, and study participants told their medicine is delayed.
• Not ideal for: People looking into real retatrutide for the first time. Start with retatrutide availability.
• The factor that matters most: Who was supplying it: a Lilly study, a doctor-managed program, or a seller.

Your retatrutide supply stopped. Who do you call?

The right next step depends on where your retatrutide came from. A seller going quiet, a seized package, and a study-site delay are three different problems with three different fixes. Find your row.

One honest limit first: we can't check what's in your vial or when a study site gets its next shipment. What we can do is point you to the person who can actually answer, and tell you what to ask.

Need help right now? If you think you've had a harmful reaction, call Poison Control at 1-800-222-1222. It's free and open 24/7. If someone collapses, has a seizure, has trouble breathing, or can't be woken up, call 911.

Once someone is handling your care, the next question is what comes after retatrutide. The right GLP-1 path isn't the same for everyone. It depends on your state, your insurance and formulary (your plan's drug list), whether you want FDA-approved or compounded medicine, a shot or a pill, and your budget. Use The RX Index's Find My GLP-1 Path tool to compare GLP-1 paths and advertised prices based on your preferences. It's free, and no email is needed to see your result. The tool doesn't confirm insurance coverage or decide whether a medicine is right for you; your insurer and clinician handle those decisions.

Retatrutide shortage status today (checked October 17, 2026)

Retatrutide isn't available as an approved retail prescription in the U.S. Lilly is studying it in clinical trials. That is different from a seller offering "research peptides" for personal use, and a seller running out doesn't create a lawful source.

Does "out of stock" mean an FDA shortage?

No. FDA calls something a drug shortage when national demand for a drug on the U.S. market is bigger than its supply. Retatrutide isn't FDA-approved or on the current shortage list. FDA separately says it cannot be compounded under federal law. A seller's stock problem doesn't change those facts.

Approval alone isn't the test. FDA also helps with shortages of some older, medically necessary drugs that never had modern approval. So the "it's unapproved, therefore it can't be a shortage" shortcut is wrong (FDA shortage FAQ).

Here's the same three-question test, run on four drugs:

Sources: FDA liraglutide shortage record, checked Oct. 17, 2026; FDA's semaglutide and tirzepatide notices and court updates; current shortage database.

These grace periods covered shortage-related rules, not blanket permission to make any version of a drug. The 503A and 503B routes are explained below.

One more thing worth knowing. FDA says that when a pharmacy can't find a medicine, it's usually a temporary local supply problem, not a national shortage (FDA). A seller's "out of stock" page tells you even less than that.

For what happened to compounded copies once real shortages ended, see GLP-1 compounding rules after a shortage ends.

Why are sellers pulling retatrutide?

Pressure is coming from four directions: FDA warning letters, Lilly lawsuits, customs seizures, and payment and shipping companies being asked to cut sellers off. These actions can disrupt sellers. They don't prove why your seller stopped, or that Lilly ran out of study medicine. Here are documented actions and warnings.

A lawsuit states allegations, not a court finding. The August entry is a filing event, not a count of all current cases. For the court history, see our page on Lilly's retatrutide lawsuits.

"Are they banning it so big pharma can cash in?"

This isn't a new October 2026 ban. FDA's September 2025 letter already said retatrutide failed the federal compounding rules and that selling those products violated federal law. Lilly does have a business stake: it's developing retatrutide. That stake and FDA's safety concerns can both be real, and neither makes a vial from a website safer.

Is it still out there?

Some sellers kept listing it after warnings. A Public Citizen review found that FDA had sent 14 warning letters to retatrutide sellers since 2024. By May 2026, 8 of those companies were still selling it (Public Citizen). Available isn't the same as legal, and it isn't the same as safe.

Can a compounding pharmacy make retatrutide to fill the gap?

No. FDA says retatrutide can't be used in compounding under federal law. It isn't part of an approved drug, has no applicable monograph (an official drug-standard entry), and isn't on the relevant 503A or 503B ingredient lists. It also isn't on the current shortage list. A seller running out creates no exception (FDA's explanation).

Two quick definitions. 503A compounding generally serves an identified patient with a prescription. A 503B outsourcing facility can also make batches without patient-specific prescriptions. Neither route permits compounded retatrutide under FDA's current position.

So if you see "compounded retatrutide," "pharmacy-grade retatrutide," "generic retatrutide," or "GLP-3," treat it as a red flag. A doctor's signature doesn't change that. If you already used one of these products, our guide to compounded retatrutide walks through your label, records, and next steps.

Is the retatrutide I already have safe?

We can't confirm that your vial is safe, and a seller's claim isn't proof. Retatrutide products sold online for personal use are not FDA-approved. FDA has not reviewed them for safety, effectiveness, or quality (FDA). Lilly says illicit products may contain unknown ingredients, contaminants, too much or too little drug, or the wrong drug entirely (Lilly FAQ).

Here's what has been reported so far. Each line says what kind of evidence it is.

What about the seller's lab report, the "COA" (certificate of analysis)? It reports tests for a stated sample or batch. Check which tests it lists, including whether it reports sterility testing, and which batch it covers (FDA guidance, section 11.4). You still need evidence that your vial matches the tested material and was handled correctly before it reached you. A COA isn't FDA approval.

Don't stretch, split, or "taper" what you have based on a website or a forum. We don't give dosing for an unapproved drug. Your study team or treating clinician should handle your care plan. Take this list to a clinician instead:

• The product name exactly as it appears on the label
• Where you bought it, and the order page or receipt
• How much you used and how often
• When you started and when you stopped
• Any symptoms, and when they began
• Every other medicine you take, especially insulin or other diabetes medicine

If something feels wrong, use the Poison Control and 911 numbers under the table at the top. You can also report a bad reaction or a suspect product to FDA MedWatch. Reporting helps others, but it doesn't replace care.

In a Lilly study? Leave the call with a plan

If you're in a Lilly study, your study team decides what happens when your medicine is delayed. You don't need to guess, and you shouldn't take advice from other participants online. Ask for written instructions, a decision about your next visit, and a set time for your next update.

The same goes if a doctor already manages your treatment through a formal access program: that doctor's team is your contact.

Here's a message you can copy and send to your study team:

Hello, I was told my study medicine may be delayed. Please confirm whether this affects my next visit or my treatment plan. Can you send me written instructions, tell me whether my visit is still needed, and give me a contact and a date for the next update? Please also tell me who to contact if I feel unwell or have a question before then. I'll follow the study team's instructions on any treatment changes.

Say your next study visit is Tuesday and you've already booked the day off. Before you drive in, send the message above and ask one thing: is the visit still needed if the medicine isn't there? A clear answer from your coordinator beats a guess built from another participant's post.

Looking for a study to join instead? Our retatrutide clinical trials guide reports which studies are listed as recruiting. Confirm openings with the study site.

When will retatrutide actually be available?

A normal pharmacy prescription needs FDA approval and a commercial launch. Lilly's Sept. 29, 2026 release says it plans to apply for approval in the first quarter of 2027. That is a planned filing, not an approval date. The sources checked here establish no date when a pharmacy will be able to fill it.

For now, Lilly's public FAQ points to its clinical trials. Lilly also has a general expanded-access process for requests made by a treating doctor. We could not confirm the current retatrutide-specific program record, so this page does not promise that route is open. If a doctor already manages your formal access, ask that doctor's team about your supply.

For the broader access question, see retatrutide availability and our early access guide. Ask your doctor to confirm any program's current terms with Lilly.

Will there be a real shortage once it's approved?

No one knows yet. Semaglutide and tirzepatide both had national shortages as demand grew (FDA). Lilly has announced manufacturing investments that include retatrutide, but those announcements don't establish stock at launch (Lilly, Jan. 30, 2026). Treat any "it'll be easy to get" or "it'll be impossible to get" claim as a guess.

What if you need weight care now?

If you need help with your weight now, FDA-approved GLP-1 medicines are available today with a prescription. Zepbound (tirzepatide) is Lilly's approved drug that works on two of retatrutide's three targets. None of these is retatrutide, and a clinician decides what fits you.

Start with your own doctor first if you have type 1 diabetes, are pregnant or planning to be, are under 18, have a history of an eating disorder, or have a personal or family history of medullary thyroid cancer or MEN 2 (multiple endocrine neoplasia syndrome type 2). The options below aren't your first step. These situations need different kinds of medical review; they aren't all blanket bans on treatment. Zepbound, Wegovy, and Foundayo all list medullary thyroid cancer history and MEN 2 as reasons not to use them. Our page on FDA-labeled contraindications explains that distinction.

If you've already tried an approved GLP-1, say so. Tell your clinician what you took, what happened, and what you can afford. That history belongs in the decision.

Sources: current U.S. prescribing information for Zepbound (revised Aug. 2026), Wegovy (revised June 2026), and Foundayo (revised July 2026); Lilly's retatrutide FAQ.

Want the deeper comparison? See FDA-approved alternatives to discuss with your clinician.

What a lawful start costs: the whole receipt

First month of membership plus a first 30-day starter fill of Wegovy pill or Foundayo: $39 + $149 = $188, if prescribed, before any extra fees. Ro bills membership and medicine separately.

People who bought vials online often worry approved medicine is out of reach. Here's the real math at one telehealth provider, Ro, with the membership and the medicine shown as separate charges. Prices are from Ro's pricing page, checked Oct. 17, 2026.

Ro membership: $39 for the first month (refunded if you're not eligible). After that, $149/month on the monthly plan, or $74/month on the 12-month plan, which is $888 paid upfront after the intro month. The $74 is a monthly equivalent, not a monthly payment. Medication is extra.

The offer rules change the bill:

• Wegovy pen: NovoCare limits the $199 offer to eligible new patients' first two 28-day starter fills. The prescription must be written and received by the pharmacy by Dec. 31, 2026, and shipped by Jan. 31, 2027. "New" means you haven't previously filled a Wegovy injection prescription through NovoCare or NovoCare Legacy. Signing up alone does not meet those terms. NovoCare terms
• Foundayo: The reduced 2.5 mg and 5.5 mg prices last through Dec. 31, 2026; signing up now does not lock them in. Their regular prices are $199 and $299. To keep the $299 offer at 14.5 mg or 17.2 mg, the next refill purchase must be within 45 days of delivery of the prior fill. The regular price without that offer is $349. Lilly terms
• Zepbound KwikPen: To keep the $449 offer at 7.5–15 mg, buy the next refill within 45 days of delivery of the prior fill. Lilly's regular self-pay prices without that offer are $499 at 7.5 mg and $699 at 10–15 mg. Lilly terms

These are prices for prescribed strengths, not instructions to start or change a dose. Your clinician decides the medicine and dose. A 28-day medication fill is not a calendar month of membership.

Next monthly membership payment plus a 30-day fill, if prescribed at the next strength: Wegovy pill 4 mg is $149 + $199 = $348. Foundayo 2.5 mg is $149 + $149 = $298 while its offer applies. Those totals are not fixed monthly prices for the whole treatment.

The membership includes provider care, support with insurance paperwork, and lab testing if ordered. Ro's terms include up to 24 medical consults a year; extra consults cost $15 each, and additional lab tests have separate fees. Ro advertises free shipping for its delivery route. KwikPen needles are separate injection supplies; confirm whether Ro adds a charge for them at checkout (LillyDirect). Lilly's offer terms also allow taxes and fees. The examples above cover the stated membership and medicine charges; they do not assume those possible extras are zero.

Before you prepay: Membership renews automatically. Ro's terms say paid membership fees are nonrefundable and require cancellation at least 48 hours before renewal to avoid the next charge. The stated refund if you're ineligible is a separate intro offer. Ro terms

Ro says its cash medication prices match LillyDirect, NovoCare, and TrumpRx. So if your own doctor already prescribes, compare buying direct too. You may not need another care membership.

Have Medicare or Medicaid? Start with your plan and your own doctor. Those programs have their own rules, and that's the right first call.

If you have insurance through work or the marketplace, find out whether your plan might cover an approved GLP-1 before you pay cash. Ro's official coverage check is free. It checks the Ozempic pen, Wegovy pen, and Zepbound autoinjector pen; it does not check the Wegovy pill, Foundayo, or Zepbound KwikPen. You provide insurance details and get a report by email. Ro can help with prior-authorization paperwork if you enroll in its care program. Coverage isn't guaranteed, and a clinician still has to approve treatment.

Want Ro's ongoing care too? Its next screen starts with a quiz about the options you want to explore.

Paid link.

If you're paying cash and want an FDA-approved medicine, Ro lists its membership and medicine prices separately. Get started for $39, then $149/month, or $888 prepaid for the annual plan after the intro month. Medication is extra. Use its options quiz to explore the cash-pay route.

Paid link.

Prefer a compounded medicine? Know what you're choosing first. Compounded drugs are not FDA-approved, and FDA doesn't review them for safety, effectiveness, or quality before they reach patients (FDA). They aren't a retatrutide substitute. Our guide to compounded vs. brand-name GLP-1s lays out the tradeoffs.

What we actually verified

We checked FDA, Lilly, federal customs, official trial records, health alerts, and provider sources on October 17, 2026. These checks show public status and published prices. They can't confirm what's in your vial, when your study site gets its next shipment, or whether you'll be approved for any treatment.

We didn't buy, test, or use any retatrutide product, and we don't track or link to sellers. We did not complete a paid intake or submit insurance or health details. This page has no medical reviewer.

See how we evaluate treatment paths.

Retatrutide shortage FAQ

Is there a retatrutide shortage?

Retatrutide isn't FDA-approved and isn't on FDA's current drug shortage list, checked October 17, 2026. There is no approved retail supply to restock. If you're in a Lilly study and told your medicine is delayed, that's a real issue for your study team to manage. A seller's stockout is a different problem.

What's causing the supply problem? Why did sellers stop?

FDA warning letters, Lilly's lawsuits, customs seizures of peptide shipments, and requests to cut off payment and shipping services all put pressure on sellers. An "out of stock" page can't tell you which, if any, affected a given seller. The dated timeline above shows the actions we verified.

Is retatrutide banned?

It isn't FDA-approved for sale as a medicine, and FDA says it cannot be compounded under federal law. FDA's September 2025 warning letter already stated that selling those retatrutide products violated federal law. This isn't a new October 2026 ban.

Is retatrutide on FDA's drug shortage list?

No. Retatrutide was absent from the FDA database when checked on October 17, 2026. A seller saying "out of stock" is not an FDA shortage finding. Approval status alone isn't the test; FDA also handles some medically necessary older unapproved drugs.

Will a study supply delay mean extra visits?

It depends on your study's plan. Before you take time off or travel, ask your coordinator whether the visit is still needed and what they can confirm first. Don't cancel a required visit because of another participant's experience.

Can a compounding pharmacy make retatrutide during a shortage?

No. FDA says retatrutide can't be used in compounding under federal law. A seller running out doesn't create an exception.

When will retatrutide be back in stock?

There is no approved retail product to restock. Lilly plans to apply for FDA approval in the first quarter of 2027, according to its Sept. 29 release; that is not a pharmacy launch date. For a delayed study shipment or an existing formal access arrangement, ask the team managing your treatment.

Can I restart when I get more?

Ask your study doctor or your own clinician for instructions that fit you. Don't use a website or a forum to decide a restart dose, make up missed doses, or switch products.

Did people die from retatrutide?

We could not verify the underlying records behind the reported deaths, so we can't establish a death count or cause here. FDA explains that an adverse-event report does not prove a drug caused the event; reports can be incomplete and medically unconfirmed. That uncertainty doesn't establish that an unapproved vial is safe. If you're concerned about what you used, take the product details to a clinician.

What's the closest legal option to retatrutide?

If you mean hormone targets, Zepbound (tirzepatide) is Lilly's approved weekly shot that acts on two of retatrutide's three targets. That does not make it a substitute. If you mean the best choice for your care, a clinician needs your health history and treatment goals.

Still not sure which GLP-1 path fits you? Try The RX Index's free Find My GLP-1 Path tool to compare paths and advertised prices — no email needed.

Sources

Sources checked October 17, 2026. Publication, policy, and label-revision dates below are the sources' own dates.

1. FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current Oct. 1, 2026).
2. FDA — Frequently Asked Questions about Drug Shortages; current and resolved shortage database.
3. FDA — Drug Shortages: Liraglutide Injection.
4. FDA — Compounding policy, shortage resolutions, and court updates (includes March 5 and April 24, 2025 court decisions and later FDA notices).
5. FDA warning letters — GLP-1 Solution, Sept. 9, 2025; Gram Peptides, Mar. 31, 2026; Aug. 24, 2026 letters to Peak Performance Peptides, Royal Peptides, NuScience Peptides, Tex Peptides, and Peptide Partners.
6. FDA — MedWatch reporting; Adverse Event Monitoring System public dashboard and data limitations.
7. Eli Lilly — What to Know About Retatrutide (FAQ updated Sept. 2026).
8. Eli Lilly — Announced retatrutide lawsuits and requests to platforms, payment companies, and regulators (Aug. 12, 2026).
9. Eli Lilly — TRIUMPH-2 release, including planned Q1 2027 filing (Sept. 29, 2026).
10. Eli Lilly — General expanded-access policy; trial records for TRIUMPH-1, TRIUMPH-7, and TRIUMPH-8.
11. U.S. Customs and Border Protection — Cincinnati seizures of more than 5,000 peptide shipments (Mar. 31, 2026).
12. Victoria Department of Health — Toxicity linked to unapproved peptide product labelled Retatrutide (issued and updated June 19, 2026).
13. Public Citizen — Its investigation of hospitalizations, enforcement gaps, and unapproved retatrutide products (June 16, 2026; seller count describes May 2026).
14. Eli Lilly — Pennsylvania manufacturing investment, including retatrutide (Jan. 30, 2026).
15. Current U.S. prescribing information — Zepbound (Aug. 2026); Wegovy (June 2026); Foundayo (July 2026).
16. Ro — Weight loss program pricing; terms of use; official insurance checker; options quiz; advertised delivery service.
17. NovoCare — Pharmacy terms, starter-offer eligibility, and fill sizes.
18. Eli Lilly — Foundayo savings terms; Zepbound savings terms; LillyDirect Zepbound supply information.
19. Poison Control — poison.org.
20. FDA — Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, section 11.4, Certificates of Analysis.